Patient-Friendly Explanation

Ecnoglutide is a new medication for type 2 diabetes and weight loss that belongs to the same family as Ozempic and Wegovy. It is given as a once-weekly injection and helps control blood sugar while also reducing appetite. Early studies show it can produce meaningful weight loss.

Clinical Definition

Ecnoglutide is an investigational long-acting GLP-1 receptor agonist administered once weekly by subcutaneous injection. It enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying; sustained receptor occupancy supports reductions in HbA1c and body weight in clinical trials.

Why It Matters

As a next-generation GLP-1 therapy, ecnoglutide may offer another option for patients who do not tolerate or respond to existing agents. A NuLifeCare Singapore doctor can assess whether a GLP-1 agonist fits your weight management plan.